Specific Instruments for Caregiving Competence Among Family Caregivers of Cancer Patients: A COSMIN Systematic Review of Psychometric Properties.

Semin Oncol NursJul 24, 2026 (epub)
Clinical ResearchOncology (Medical)

Menglin Zou, Zheng Liang, Yanan Wang et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review evaluated the psychometric properties of instruments measuring caregiving competence among family caregivers of cancer patients. Seven studies were analyzed, focusing on three specific instruments. The Care Competency Scale for Family Caregivers in Home Palliative Care and the Caring Ability of Family Caregivers of Patients with Cancer Scale received Category B recommendations, indicating adequate content validity, while the Caregiver Caregiving Self-Efficacy Scale-Oral Cancer was rated Category C due to inadequate criterion validity.

Key findings

  • The Care Competency Scale for Family Caregivers in Home Palliative Care received a 'very low' evidence grade.
  • The Caring Ability of Family Caregivers of Patients with Cancer Scale showed 'moderate' structural validity.
  • The Caregiver Caregiving Self-Efficacy Scale-Oral Cancer was rated Category C for inadequate criterion validity.

Why it matters

Understanding the psychometric properties of caregiving instruments is crucial for clinicians to assess and enhance the competencies of family caregivers, ultimately improving the quality of home-based cancer care.

Source

PubMed · PMID 42493286

Published in Semin Oncol Nurs. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.